Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks Japanese Distribution Deal

NEW YORK (GenomeWeb News) – Following its first distribution deal for Asia, Link Technologies today announced another deal covering that region, this time with Japanese firm GeneDesign

Under the terms of the agreement, GeneDesign will represent Link throughout Japan. The agreement comes about a month after Link forged a distribution agreement with Zirench Technology covering China.

"By working with GeneDesign, we will be able to provide local access to our high quality products and offer our expert support services to customers throughout Japan," Link CEO John Bremner said in a statement. "This level of accessibility is something we are very keen to continue to develop within Asia and worldwide, and forms part of our ongoing strategic plans for development and growth."

Financial and other terms were not disclosed.

Link is based in Bellshill, Scotland and supplies specialty reagents for oligonucleotide synthesis and modification. GeneDesign is a contract manufacturing organization headquartered in Osaka, Japan. It also provides contract research organization services focused on oligonucleotide chemistry.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.